Under the agreement, Glenmark is expected to manufacture the FDA approved products exclusively for Taro USA.
Taro USA’s branded division, TaroPharma, a division that offers dermatologists and pediatricians proprietary product lines for a variety of patient needs, is expected to be the exclusive US distributor of the product. Glenmark is expected to receive milestone payments and a royalty on sales.
Glenmark Generics said that the company sells its FDF products in the US and EU, as well as its oncology FDF products in South America. Glenmark Generics claims to supply APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.
Taro Pharmaceutical Industries is a science-based pharmaceutical company into discovery, development, manufacturing and marketing of healthcare products.